Free Trial
NASDAQ:IRD

Opus Genetics 5/16/2025 Earnings Report

Opus Genetics logo
$0.95 0.00 (-0.42%)
As of 02:05 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Opus Genetics EPS Results

Actual EPS
N/A
Consensus EPS
-$0.34
Beat/Miss
N/A
One Year Ago EPS
N/A

Opus Genetics Revenue Results

Actual Revenue
N/A
Expected Revenue
$4.00 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Opus Genetics Announcement Details

Quarter
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Opus Genetics Earnings Headlines

Silver Demand Is Soaring-Supply Can't Keep Up
Silver demand hit 1.16 billion ounces in 2024-while supply fell short again for the fourth year in a row. Industrial demand is rising fast, but new supply isn't keeping pace. For investors, that opens the door to one key question: who already has it? One project in N. America just reported high-grade results at a time when ounces in the ground are becoming harder to find-and more valuable.
See More Opus Genetics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Opus Genetics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Opus Genetics and other key companies, straight to your email.

About Opus Genetics

Opus Genetics (NASDAQ:IRD) Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.

View Opus Genetics Profile

More Earnings Resources from MarketBeat